Drug Trial Radar · NCT07442006
Glycemic Variability of Combination Therapies in T2DM
Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
178
Planned (sponsor's estimate)
Start
Oct 29, 2025
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- JW PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Mar 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Glycemic Variability of Combination Therapies in T2DM
Conditions
- Type 2 Diabetes Mellitus (T2DM)
Interventions
Empagliflozin/MetforminDrug
5/500 mg, 5/1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)
AnagliptinDrug
100 mg, for 12 weeks (PO, BID)
MetforminDrug
500 mg, 1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)
Empagliflozin/LinagliptinDrug
10/5 mg, for 12 weeks (PO, QD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in Mean Amplitude of Glycemic Excursion (MAGE) from baseline to week 12Time frame: Baseline to week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.